In this COVID-perspective 3 specialists in dermato-venereology reviews on some of the limited available literature about skin manifestations in COVID-19.

Medicinskt test om PAD/CAD

Testa din kunskap om arterosklerotisk sykdom, PAD/CAD. Aterosklerotisk sjukdom i perifera och hjärtkärl drabbar många patienter årligen och ökar både sjuklighet och dödlighet. Klicka och testa din kunskap om aterosklerotisk sjukdom (PAD / CAD). Se gärna BestPractice Nordic MEDtalks före du gör quizzen: Perifer arteriell sjukdom (PAD) Klinisk hantering och behandling av PAD Bestämning av ankel-brakialindex (ABI) [gravityform id="8" title="true" description="true"]

Keep up with the mass amount of information about COVID-19 being rolled out online. In this perspective we present three of this week’s COVID-19 headlines from Reuters, Medscape & The Lancet.

MEST SETE MEDtalks

ASCO 2019: Breakthrough for CDK4/6 inhibitor + endocrine therapy in premenopausal patients with HR+/HER2− advanced breast cancer   Se hele webinar

ASCO 2019: Breakthrough for CDK4/6 inhibitor + endocrine therapy in premenopausal patients with HR+/HER2− advanced breast cancer

<script src="https://fast.wistia.com/embed/medias/4rwno0og6n.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_4rwno0og6n videoFoam=true" style="height:100%;position:relative;width:100%"><div class="wistia_swatch" style="height:100%;left:0;opacity:0;overflow:hidden;position:absolute;top:0;transition:opacity 200ms;width:100%;"><img src="https://fast.wistia.com/embed/medias/4rwno0og6n/swatch" style="filter:blur(5px);height:100%;object-fit:contain;width:100%;" alt="" onload="this.parentNode.style.opacity=1;" /></div></div></div></div>
ASCO 2019: Breakthrough for CDK4/6 inhibitor + endocrine therapy in premenopausal patients with HR+/HER2− advanced breast cancer&nbsp;&nbsp;&nbsp;<a href='https://bestprac.se/webinar/asco-2019-breakthrough-for-cdk4-6-inhibitor-endocrine-therapy-in-premenopausal-patients-with-hr-her2%e2%88%92-advanced-breast-cancer/'>Se hele webinar
ASCO 2019: Breakthrough for CDK4/6 inhibitor + endocrine therapy in premenopausal patients with HR+/HER2− advanced breast cancer

ASCO 2019: Updated overall survival for treatment of locally advanced or metastatic triple-negative breast cancer

<script src="https://fast.wistia.com/embed/medias/rp2kqsxgnz.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_rp2kqsxgnz videoFoam=true" style="height:100%;position:relative;width:100%"><div class="wistia_swatch" style="height:100%;left:0;opacity:0;overflow:hidden;position:absolute;top:0;transition:opacity 200ms;width:100%;"><img src="https://fast.wistia.com/embed/medias/rp2kqsxgnz/swatch" style="filter:blur(5px);height:100%;object-fit:contain;width:100%;" alt="" onload="this.parentNode.style.opacity=1;" /></div></div></div></div>
ASCO 2019: Updated overall survival for treatment of locally advanced or metastatic triple-negative breast cancer&nbsp;&nbsp;&nbsp;<a href='https://bestprac.se/webinar/asco-2019-updated-overall-survival-for-treatment-of-locally-advanced-or-metastatic-triple-negative-breast-cancer/'>Se hele webinar
ASCO 2019: Updated overall survival for treatment of locally advanced or metastatic triple-negative breast cancer

EHA 2019: Venetoclax plus obinutuzumab improves PFS and MRD negativity in patients with previously untreated CLL and comorbidities

<script src="https://fast.wistia.com/embed/medias/abbfjgn32v.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_abbfjgn32v videoFoam=true" style="height:100%;position:relative;width:100%"><div class="wistia_swatch" style="height:100%;left:0;opacity:0;overflow:hidden;position:absolute;top:0;transition:opacity 200ms;width:100%;"><img src="https://fast.wistia.com/embed/medias/abbfjgn32v/swatch" style="filter:blur(5px);height:100%;object-fit:contain;width:100%;" alt="" onload="this.parentNode.style.opacity=1;" /></div></div></div></div>
EHA 2019: Venetoclax plus obinutuzumab improves PFS and MRD negativity in patients with previously untreated CLL and comorbidities&nbsp;&nbsp;&nbsp;<a href='https://bestprac.se/webinar/eha-2019-venetoclax-plus-obinutuzumab-improves-pfs-and-mrd-negativity-in-patients-with-previously-untreated-cll-and-comorbidities/'>Se hele webinar
EHA 2019: Venetoclax plus obinutuzumab improves PFS and MRD negativity in patients with previously untreated CLL and comorbidities

EHA 2019: Highly effective combination for initial therapy for young, fit CLL patientsEHA 2019: Highly effective combination for initial therapy for young, fit CLL patients

<script src="https://fast.wistia.com/embed/medias/abbfjgn32v.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_abbfjgn32v videoFoam=true" style="height:100%;position:relative;width:100%"><div class="wistia_swatch" style="height:100%;left:0;opacity:0;overflow:hidden;position:absolute;top:0;transition:opacity 200ms;width:100%;"><img src="https://fast.wistia.com/embed/medias/abbfjgn32v/swatch" style="filter:blur(5px);height:100%;object-fit:contain;width:100%;" alt="" onload="this.parentNode.style.opacity=1;" /></div></div></div></div>
EHA 2019: Highly effective combination for initial therapy for young, fit CLL patientsEHA 2019: Highly effective combination for initial therapy for young, fit CLL patients&nbsp;&nbsp;&nbsp;<a href='https://bestprac.se/webinar/eha-2019-highly-effective-combination-for-initial-therapy-for-young-fit-cll-patientseha-2019-highly-effective-combination-for-initial-therapy-for-young-fit-cll-patients/'>Se hele webinar
EHA 2019: Highly effective combination for initial therapy for young, fit CLL patients

More perspectives on their way

For more than two weeks we have been sharing a daily COVID-19 Perspective with you, and we are overwhelmed by the interest and positive feedback. The average opening rate of over 50% tells us that this initiative is well received. We will keep following the news about COVID-19 and pick the most perspectives to share with you, but from Easter onwards we will decrease the cadence to twice a week. Every Thursday you will receive our most popular theme: COVID-19 in the big journals, and every Tuesday we will send you another COVID-19 ‘must-read’ perspective. If you have feedback or ideas for the next COVID-19 Perspective, please do not hesitate to let us know on a direct line to Editor-in-Chief Jan Andreasen: jan@bpno.dk

Inflammatory bowel disease is not normally associated with an increased risk of infections. However, immune modulating therapy entails a general higher risk for both bacterial and viral infections. This interrelation could be relevant in the current outbreak of COVID-19 where infected patients undergoing immune modulating therapy are thought to have increased risk for severe and complicated disease course. “Danish Society of Gastroenterology and Hepatology” has recommended to maintain the immune modulating therapy during the epidemy but endorse extra caution and awareness of preventing transmission.   By Johan Burisch, MD, PhD, Gastrounit, Medical division, Copenhagen University Hospital Hvidovre  Klaus Theede, chief physician, MD, PhD, Gastrounit, Medical division, Copenhagen University Hospital Hvidovre  Inflammatory bowel disease (IBD) is, despite the underlying dysregulation of the innate immune system, not necessarily associated with a higher risk of infection. However, the patients become immunosuppressed and thus have an increased risk of getting serious opportunistic infections by the therapy they receive, first and foremost the use of prednisolone, thiopurines, methotrexate and biological medicines, including antibodies against tumor necrosis factor alpha (anti-TNF-alpha).1  Every group of medicines entails a higher risk of infections. It is difficult to quantify the exact risks, that is known to variate from the different medicine groups. But it must be assumed that the immunosuppression increases when combining more than one drug. For instance, one international study found that the relative risk for opportunistic infections increased from an odds ratio on 2,9 (95% Cl: 1,5-5,3) when using one immune modulating drug to 14,5% (95% Cl: 4,9-43) when using two or more immune modulating drugs.2   In…

Inter-Agency Standing Committee has launched a $2 billion response plan in order to assist these countries. Read about the plan in this perspective.

#Senaste Tidskrift

Dermatologi

Nr. 1 • mars 2020
Årgång 11
  • Malignt melanom
  • Atopisk dermatit
  • Allergi